anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a pearl mind calming and convulsion arresting black rice cake and a production method thereof. The black rice cake contains the following raw materials in parts by weight: 100-120 parts of black glutinous rice, 30-40 parts of glutinous rice, 30-40 parts of panicum miliaceum, 10-20 parts of orange powder, 10-15 parts of coconut powder, 8-10 parts of traditional Chinese medicine powder, 2-4 parts of spice powder, and 2-4 parts of Wuhua sauce. The traditional Chinese medicine powder is prepared from pearl, herba artemisiae anomalae, rhizoma alismatis, herba spirodelae, herba scutellariae barbatae, pteris multifida, herba abri, dried gingers, turnip, radix notoginseng, radix angelicae sinensis, and native star anises. The main steps of the production method are as follows: grinding, Chinese traditional medicinal powder preparing, spice powder preparing, Wuhua sauce preparing, mixing, steaming, and shaping. The pearl mind calming and convulsion arresting black rice cake is prepared from the purely natural raw materials. A combination of a Chinese herbal medicine formula and the rice cake is very important. The delicious rice cake is eaten by people, the physical symptoms of people can be effectively improved and the medicines are reasonable and effective in collocation. The rice cake can be eaten for a long period of time and has the efficacies of calming mind and arresting convulsion, improving eyesight and relieving eye opacity, and removing toxins and promoting tissue regeneration.
Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
The present invention provides an oral disintegration tablet of a proton pump inhibitor, which comprises omeprazole or derivatives of omeprazole as the active components of the medicine. The oral disintegration tablet is prepared by using omeprazole (5-methoxy group-2-{[(4-methoxy group-3, 5-dimethyl-2-pyridyl)-methyl]-sulfoxide}-1H-benzimidazole) or derivatives of omeprazole as raw materials by various pharmacy methods, coating a protective coating layer, and adding a filling agent, a disintegrating agent, a corrigent, a flow aid, a lubricator, etc. as auxiliary materials by a specific preparation method. Different types of plasticizing agents can be added into the protective coating layer according to different conditions. The oral disintegration tablet of the present invention has the characteristics of good friability, quick disintegration, good taste, no sand feeling, portability, convenience for storage, transport and taking, etc. Particularly, the oral disintegration tablet can be taken under a condition without water and can quickly take effects. Thus, the compliance of patients is improved, and the therapeutic effect of medicines is enhanced.
OBJECTIVES: I. Identify a priming schedule of sargramostim (GM-CSF) that reduces the percentage of progenitor cells in cycle at the time of chemotherapy administration in patients with advanced malignancies. II. Determine the maximum tolerated dose and toxic effects of topotecan when administered with sargramostim in these patients. III. Conduct a preliminary assessment of the activity of this topotecan regimen in these patients.

OUTLINE: This is a dose escalation study of topotecan. Patients receive priming with sargramostim (GM-CSF) on days -4 through -2. On day 0, topotecan IV is administered over 30 minutes. Cohorts of 6 patients receive escalating doses of topotecan. The maximum tolerated dose (MTD) is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity (DLT). Sargramostim resumes on day 1 following topotecan, and continues for 5 days or until sufficient hematologic recovery. The next course of topotecan is given 48 hours later. Treatment repeats every 6 weeks for 4 courses. Patients are followed every 3 months for the first year, then every 6 months thereafter.

PROJECTED ACCRUAL: 15-25 patients will be accrued for the duration of 18 months.
Drug: Calcitriol The intervention group will be given calcitriol at a dose of 0.25 mcg/day for six months in the form of capsules that have been marked and numbered. The drugs will be taken through the RSCM pharmacy once a month during visit and the allocation will be given using drug labels that are sealed and packaged identically.
Experimental group will be selected from the branches 3rd and 4th grade. 3 branches will be selected for the experimental group. Branches will be determined by drawing. In order not to interfere with the education of students during the training, the groups will be designated as class branches.
INTRODUCTION: Metastatic gastrointestinal stromal tumour (GIST) is considered incurable, and life-long treatment with tyrosine kinase inhibitors is recommended. We investigated whether selected patients with metastatic GIST may remain in durable remission despite imatinib discontinuation.
PATIENTS: In this 1-group, prospective, multicentre phase II trial selected patients with oligometastatic (≤3 metastases) GIST discontinued imatinib treatment. Eligible patients had been treated with imatinib >5 years without progression and had no radiologically detectable metastases after metastasectomy, radiofrequency ablation (RFA) or complete response to imatinib. The primary endpoint was progression-free survival (PFS) 3-years after stopping imatinib. Overall survival (OS) and quality of life (QoL) were secondary endpoints.
RESULTS: The trial closed prematurely due to slow accrual. Between January 5, 2017, and June 5, 2019, 13 patients were enrolled, of whom 12 discontinued imatinib. The median follow-up time was 55 months (range, 36 to 69) after study entry. Five (42%) of the 12 eligible patients remained progression free, and seven (58%) progressed with a median time to progression 10 months. Median PFS was 23 months and the estimated 3-year PFS 41%. Six of the seven patients who progressed restarted imatinib, and all six responded. Three-year OS was 100%, and all patients were alive at the time of the study analysis. QoL measured 5 and 11 months after discontinuation of imatinib demonstrated improvement compared to the baseline.
INTERPRETATION: A substantial proportion of selected patients with oligometastatic GIST treated with imatinib and metastasis surgery/RFA may remain disease-free for ≥3 years with improved QoL after stopping of imatinib.
AIM: As the size of the elderly population gradually increases, musculoskeletal disorders, such as sarcopenia, are increasing. Diagnostic techniques such as X-rays, computed tomography, and magnetic resonance imaging are used to predict and diagnose sarcopenia, and methods using machine learning are gradually increasing. This study aimed to create a model that can predict sarcopenia using physical characteristics and activity-related variables without medical diagnostic equipment, such as imaging equipment, for the elderly aged 60 years or older.
METHODS: A sarcopenia prediction model was constructed using public data obtained from the Korea National Health and Nutrition Examination Survey. Models were built using Logistic Regression, Support Vector Machine (SVM), XGBoost, LightGBM, RandomForest, and Multi-layer Perceptron Neural Network (MLP) algorithms, and the feature importance of the models trained with the algorithms, except for SVM and MLP, was analyzed.
RESULTS: The sarcopenia prediction model built with the LightGBM algorithm achieved the highest test accuracy, of 0.848. In constructing the LightGBM model, physical characteristic variables such as body mass index, weight, and waist circumference showed high importance, and activity-related variables were also used in constructing the model.
CONCLUSIONS: The sarcopenia prediction model, which consisted of only physical characteristics and activity-related factors, showed excellent performance. This model has the potential to assist in the early detection of sarcopenia in the elderly, especially in communities with limited access to medical resources or facilities. Geriatr Gerontol Int 2024; 24: 595-602.
In our cross-sectional study; the target sample size was calculated as 299, with a population of 1350. The prevalence was 50%, the standard error was 5% in a 95% confidence interval. Between 03.01.2019 and 30.05.2019; 300 elderly volunteers who applied to the Health Sciences University Haydarpaşa Numune Training and Research Hospital Family Medicine Polyclinics for any reason, who were not diagnosed with neuropsychiatric disease, do not had physical or mental problems that would prevent them from understanding and filling the scales and do not have a health problem that require urgent intervention are included. Participants were informed, their consent was taken, and a 21-item sociodemographic form prepared by the researchers was applied. Afterwards, a 7-point Likert-type "Successful Aging Scale" (SAS) consisting of 10 questions was applied to the participants.16 The scale had two sub-components, namely "healthy lifestyle" (HL) and "adaptive coping" (AC). The values of the expressions in the scale were as "strongly agree:7, agree:6, partially agree:5, undecided:4, partially disagree:3, disagree:2, strongly disagree:1". The values for each individual were summed up and the scale was evaluated by subtracting the total score. Finally, the results from the questionnaire and the Successful Aging Scale were compared and analyzed according to subcomponents.
Ganciclovir was evaluated in three randomized, controlled trials of prevention of CMV disease in organ transplant recipients.

### 

Trial ICM 1496: In a randomized, double-blind, placebo-controlled study of 149 heart transplant recipients at risk for CMV infection (CMV seropositive or a seronegative recipient of an organ from a CMV seropositive donor), there was a reduction in the overall incidence of CMV disease in patients treated with ganciclovir. Immediately post-transplant, patients received ganciclovir for injection solution 5 mg/kg twice daily for 14 days followed by 6 mg/kg once daily for 5 days/week for an additional 14 days. Twelve of the 76 (16%) patients treated with ganciclovir vs. 31 of the 73 (43%) placebo-treated patients developed CMV disease during the 120-day post-transplant observation period. No significant differences in hematologic toxicities were seen between the two treatment groups [see Adverse Reactions (6.1)].

### 

Trial ICM 1689: In a randomized, double-blind, placebo-controlled study of 72 bone marrow transplant recipients with asymptomatic CMV infection (CMV positive culture of urine, throat or blood) there was a reduction in the incidence of CMV disease in patients treated with ganciclovir following successful hematopoietic engraftment. Patients with virologic evidence of CMV infection received ganciclovir for injection solution 5 mg/kg twice daily for 7 days followed by 5 mg/kg once daily through day 100 post-transplant. One of the 37 (3%) patients treated with ganciclovir vs. 15 of the 35 (43%) placebo-treated patients developed CMV disease during the study. At 6 months post-transplant, there continued to be a reduction in the incidence of CMV disease in patients treated with ganciclovir. Six of 37 (16%) patients treated with ganciclovir vs. 15 of the 35 (43%) placebo-treated patients developed disease through 6 months post-transplant. The overall rate of survival was higher in the group treated with ganciclovir, both at day 100 and day 180 post-transplant. Although the differences in hematologic toxicities were not statistically significant, the incidence of neutropenia was higher in the group treated with ganciclovir [see Adverse Reactions (6.1)].

### 

Trial ICM 1570: This was a randomized, unblinded study that evaluated 40 allogeneic bone marrow transplant recipients at risk for CMV disease. Patients underwent bronchoscopy and bronchoalveolar lavage (BAL) on day 35 post-transplant. Patients with histologic, immunologic or virologic evidence of CMV infection in the lung were then randomized to observation or treatment with ganciclovir for injection solution (5 mg/kg twice daily for 14 days followed by 5 mg/kg once daily 5 days/week until day 120). Four of 20 (20%) patients treated with ganciclovir and 14 of 20 (70%) control patients developed interstitial pneumonia. The incidence of CMV disease was lower in the group treated with ganciclovir, consistent with the results observed in ICM 1689.
The purpose of the present study was to evaluate the prevalence of early adiposity rebound (EAR) and factors associated with its occurrence in a cohort of extremely low birth weight infants (ELBW). We conducted a retrospective longitudinal study including ELBW infants followed-up for up to 10 years after discharge. EAR was defined as occurring before 5 years of age. A multivariate binary logistic regression analysis was performed to evaluate maternal and perinatal variables independently associated with EAR. Out of 212 ELBW infants included in the analysis, 40.6% developed EAR and 21.5% showed it before 4 years of age. Only formula milk feeding at discharge was independently associated with a higher risk of EAR. The mean BMI of children with EAR was higher than that of children without EAR. Furthermore, the prevalence of overweight and obesity was higher in the EAR group than in the timely AR group.  Conclusions: ELBW infants in our cohort developed EAR in a relatively high percentage of cases. In this already at-risk population, EAR may represent a further risk factor for an adverse metabolic outcome. Monitoring preterm infants' growth within a long-term follow-up program and promoting and supporting human milk feeding is advisable. What is Known: • Preterm-born infants are at high risk for long-term adverse health outcomes, especially cardiovascular and metabolic. • The occurrence of early adiposity rebound (EAR) is associated with the risk of later obesity and metabolic syndrome. What is New: • The occurrence of EAR in ELBW infants may represent an additional risk factor for later adverse metabolic outcomes in an already vulnerable population. • Future preventive strategies should include a long-term follow-up and the promotion of exclusive breastfeeding.
Circulating tumor cells (CTCs) shed from primary tumors must overcome the cytotoxicity of immune cells, particularly natural killer (NK) cells, to cause metastasis. The tumor microenvironment (TME) protects tumor cells from the cytotoxicity of immune cells, which is partially executed by cancer-associated mesenchymal stromal cells (MSCs). However, the mechanisms by which MSCs influence the NK resistance of CTCs remain poorly understood. This study demonstrates that MSCs enhance the NK resistance of cancer cells in a gap junction-dependent manner, thereby promoting the survival and metastatic seeding of CTCs in immunocompromised mice. Tumor cells crosstalk with MSCs through an intercellular cGAS-cGAMP-STING signaling loop, leading to increased production of interferon-β (IFNβ) by MSCs. IFNβ reversely enhances the type I IFN (IFN-I) signaling in tumor cells and hence the expression of human leukocyte antigen class I (HLA-I) on the cell surface, protecting the tumor cells from NK cytotoxicity. Disruption of this loop reverses NK sensitivity in tumor cells and decreases tumor metastasis. Moreover, there are positive correlations between IFN-I signaling, HLA-I expression, and NK tolerance in human tumor samples. Thus, the NK-resistant signaling loop between tumor cells and MSCs may serve as a novel therapeutic target.
Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
An image analysis method and an image analysis system are provided. The image analysis system includes an X-ray sensor, a computing device and a display device. The computing device is coupled to the X-ray sensor. The computing device includes a processing module and a memory module. The display device is coupled to the computing device. The processing module executes an image processing unit and an image analysis unit stored in the memory module to perform an image analysis according to dual-energy image data generated by the X-ray sensor, and outputs a lesion judgment result to the display device.
This group contains participants diagnosed with diabetes-related phenotypes other than Type 1, Type 2, or LADA, as well as those with rarer forms of the disease (based on clinical data). The validation aims to determine the algorithm's effectiveness in correctly identifying and classifying these less common phenotypes, which is critical for ensuring comprehensive and accurate diabetes classification.
The invention discloses a traditional Chinese medicine composition for preventing a pullorum disease. The traditional Chinese medicine composition comprises the following medicinal materials in parts by weight: 120 to 180 parts of red-knees herb, 120 to 180 parts of cablin potchouli herb, 120 to 180 parts of glossy privet fruit and 80 to 120 parts of astragalus. A test shows that the resistance of a chick to artificial infection of pullorum disease salmonella can be obviously improved, a strong sterilizing effect is expressed, the weight gain rate of the chick can be kept in a normal level, and the survival rate of the chick infected with the pullorum disease salmonella can be improved. Moreover, the traditional Chinese medicine composition has the characteristics of safety, non-toxicity and no drug residue, and the quality of a chicken product can be improved. The traditional Chinese medicine composition can replace antibiotics and feed additives for the poultry, the pollution of livestock products caused by drug resistance and drug residue can be effectively avoided, harmful livestock excrements, protein dosage and nitrogen pollution are reduced, and the market prospect is wide. Meanwhile, a preparation method is simple, convenient to use and lower in cost.
OBJECTIVE: To assess sudden unexpected infant death (SUID) investigations for structural inequities by race/ethnicity and geography.
METHODS: The SUID Case Registry compiles data on death investigations. We analyzed cases from 2015 to 2018 (N = 3847) to examine likelihood of an incomplete death investigation, defined as missing autopsy, missing scene investigation, or missing detailed information about where and how the body was found. We also analyzed which specific components of death investigations led to the greatest number of incomplete investigations.
RESULTS: Twenty-four percent of SUIDs had incomplete death investigations. Death scenes in rural places had 1.51 times the odds of incomplete death investigations (95% confidence interval [CI], 1.19-1.92) compared with urban areas. Scene investigations led by law enforcement were more likely to result in incomplete death investigations (odds ratio [OR] = 1.49; 95% CI, 1.18-1.88) than those led by medical examiners. American Indian/Alaska Native SUIDs were more likely than other racial groups to have an incomplete investigation (OR = 1.49; 95% CI, 0.92-2.42), more likely to occur in rural places ( P = .055), and more likely to be investigated by law enforcement ( P < .001). If doll reenactments had been performed, 358 additional cases would have had complete investigations, and if SUID investigation forms had been performed, 243 additional cases would have had complete investigations. American Indian/Alaska Native SUIDs were also more likely to be missing specific components of death investigations.
CONCLUSION: To produce equitable public health surveillance data used in prevention efforts, it is crucial to improve SUID investigations, especially in rural areas and among American Indian/Alaska Native babies.
Provided in the present invention is a taste and nutrient data processing system based on flow data collection. The system includes a collection module and a data management module, wherein the collection module includes a raw material collection module and/or an operation collection module; and includes a transformation calculation module and an error correction and determination module. Taste and nutrient elements are collected, and factors influencing the taste and nutrient elements during raw material collection and operation processes are fully taken into consideration for design of the system, such that obtained taste values and nutrient values are closer to real data. Each step is planned properly and is close to reality. Moreover, a flow standardized record is performed on the basis of the logic of a computer system, such that corresponding taste values and nutrient values are calculated according to the steps. Therefore, in the present solution, a template can also be selected according to requirements of a user. On the basis of perfect taste values and nutrient values, existing taste values and nutrient values are adjusted, that is, when a set at the right side of a calculation formula changes, it is necessary to reversely deduce specific values corresponding to different raw material operations at the left side of the equation, so as to determine a preparation flow and a raw material list, which are required for achieving an expected finished product.
Cross-linked Hyaluronic Acid 0.75%, regulated through CDRH (device). EyeGate Ocular Bandage Gel will be applied topically to both eyes (OU) four times a day. Ocular Bandage Gel use is discontinued once complete re-epithelialization has occurred in that eye.
Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization. ACT-based group therapy.
A micelle, comprises a first phospholipid, a second phospholipid, a targeting agent, conjugated to the first phospholipid, a perfluorocarbon, and a therapeutically active compound. The first phospholipid and the second phospholipid form a shell enclosing the perfluorocarbon and the therapeutically active compound. The targeting agent comprises an anti-nucleolin agent, and the therapeutically active compound comprises a chemotherapeutic agent and/or a cytotoxic agent. An emulsion may be formed, comprising a plurality of the micelles, and continuous aqueous phase. A pharmaceutical composition for treating cancer may be prepared, comprising the emulsion, and a pharmaceutically acceptable carrier. A method of treating cancer includes administering an effective amount of the pharmaceutical composition to a patient in need thereof.
There are various treatment options that can be applied to patients with lumbar disc herniation (LDH). These are basically divided into 2 categories: surgical and conservative treatment. Conservative treatment methods in the treatment of LDH aim to prevent the disease from transitioning to interventional methods and / or surgical treatment and to improve the complaints that negatively affect the quality of life. Conservative treatment; It includes informing the patient, bed rest, drug treatments, exercise, thermotherapy, electrotherapy, traction, orthoses, back school and manual therapy applications. Manual therapy; It is used to reduce pain, provide joint and tissue mobility, inhibit sympathetic reflex activity, normalize muscle tone and dissolve adhesions. Manual therapy is the manual treatment of the spine with two different applications such as manipulation and mobilization.

The clinical effects of manual therapy in LDH patients were examined. The aim of this study was to investigate the effect of manual therapy on psychological factors and quality of life in patients with lumbar disc herniation.